Covert and Overt Hepatic Encephalopathy: Diagnosis and Management.

Abstract

Hepatic encephalopathy (HE) is part of a spectrum of neurocognitive changes in cirrhosis. HE is divided into 2 broad categories based on severity: covert hepatic encephalopathy (CHE) and overt hepatic encephalopathy (OHE). CHE has a significant impact on a patient's quality of life, driving performance, and recently has been associated with increased hospitalizations and death. Likewise, OHE is associated with increased rates of hospitalizations and mortality, and poor quality of life. Given its significant burden on patients, care takers, and the health care system, early diagnosis and management are imperative. In addition, focus also should be directed on patient and family member education on the disease progression and adherence to medications. Treatment strategies include the use of nonabsorbable disaccharides, antibiotics (ie, rifaximin), and, potentially, probiotics. Other therapies currently under further investigation include L-ornithine-L-aspartate, ornithine phenylacetate, glycerol phenylbutyrate, molecular adsorbent recirculating system, and albumin infusion.

DOI: 10.1016/j.cgh.2015.06.039
0102030201520162017
Citations per Year

Citation Velocity: 4

Averaging 4 citations per year over the last 3 years.

Learn more about how we calculate this metric in our FAQ.

Cite this paper

@article{Patidar2015CovertAO, title={Covert and Overt Hepatic Encephalopathy: Diagnosis and Management.}, author={Kavish R. Patidar and Jasmohan S Bajaj}, journal={Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association}, year={2015}, volume={13 12}, pages={2048-61} }